Psoriasis: brodalumab shows sustained efficacy in 5-year extension study

  • Lebwohl MG & al.
  • Am J Clin Dermatol
  • 6 Sep 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Brodalumab was associated with sustained improvements in clinical symptoms and QoL with no new safety signals at 5 years in a phase 2 open-label extension (OLE) study.

Key results

  • 77.3% of patients maintained a static Physician’s Global Assessment score of ≤1 at week 240.
  • A ≥75% improvement in the Psoriasis Area and Severity Index was maintained for >80% of patients during weeks 4-264.
  • Mean improvement in PASI was 92.1% at week 240, whereas mean improvement in body surface area affected was 92.8%.
  • Dermatology Life Quality Index score was 0 or 1 for >67% of patients during weeks 4-264.
  • 97.8% of patients experienced treatment-emergent adverse events (TEAEs); grade ≥3 AEs were reported in 22.7% of patients.

Study design

  • 181 patients who completed a 2-week, phase 2 trial received brodalumab 210 mg every 2 weeks.
  • Funding: Ortho Dermatologics.

Limitations

  • No comparator group.
  • Potential selection bias.